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Abstract
Perivascular epithelial cell tumors (PEComas), firstly described by Bonetti in 1992, are a family of mesenchymal
tumor composed of perivascular epithelioid cells having epithelioid or spindle morphology and exhibiting
melanocytic and myogenic immunoreactivities. We herein described a 61-year-old woman who presented with
epigastric pain. Preoperative imaging studies showed that 7-cm-sized mass was located in pancreatic head and
body, and pancreaticoduodenectomy was performed. Histological findings showed that the tumor was composed
of clear epithelioid cells with abundant glycogen granules, which grew in a nested and alveolar pattern around
blood vessels. The tumor cells showed immunoreactivities for HMB-45 but did not express epithelial or endocrine
markers. These histological features indicated those of PEComa. This report underlines that we should recognize
PEComa as a preoperative differential diagnosis of pancreatic tumors.
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Background
Perivascular epithelial cell tumors (PEComas) are a fam-
ily of mesenchymal tumors composed of perivascular
epithelioid cells having epithelioid or spindle shape, clear
to granular cytoplasm, centrally located, round to oval
nucleus and inconspicuous nucleoli. Immunohisto-
chemically, these neoplastic cells exhibit melanocytic
marker, HMB-45, and occasionally myogenic marker, α-
SMA. Angiomyolipoma, lymphangioleiomyoma, and
clear cell “sugar” tumor are included in the PEComa
family. PEComas arise in various organs throughout the
body, especially in soft tissue, bone, abdominopelvic
sites, or retroperitoneal site such as the kidney, uterus,
and gastrointestinal tract, but PEComa arising in pan-
creas is extremely rare. We described a primary PEComa
occurring in the pancreatic body of a 61-year-old woman
without a history of tuberous sclerosis complexes.
Case presentation
A 61-year-old woman was referred to our hospital with
epigastralgia. Abdominal ultrasonographic examination
showed 7-cm-sized mass in the head and body of the
pancreas. Physical examination was unremarkable, and
any symptoms were not presented except for mild
epigastric tenderness. She had smoked one pack of
cigarettes per day for 32 years until quitting smoking
8 years before, but not had a history of tuberous scler-
osis complexes, malignancy, habitual alcohol consump-
tion, or diabetes mellitus.
The results of blood tests were shown in Table 1. The
serum levels of tumor markers showed no significant
abnormal findings. As for endocrinology, serum gastrin
and somatostatin levels were slightly elevated, but nega-
tive results were obtained for serum glucagon, vasoactive
intestinal peptide (VIP), serotonin, and plasma immuno-
reactive insulin (IRI).
Abdominal ultrasonographic examination showed that
gourd-shaped hypo- and iso-echoic mass, 56 mm in size,
was detected in the pancreatic head and body (Fig. 1a).
Upstream main pancreatic duct was slightly dilated,
5 mm in diameter, by extrinsic compression of the mass.
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Neither dilatation of common bile duct nor large vessel
involvement was observed.
Abdominal enhanced computed tomography (CT)
scans revealed that a solid low-density mass approxi-
mately 7 cm in diameter, which was circumferentially
well-demarcated, was located in the pancreatic body
(Fig. 1b). The tumor was shown to be derived from the
parenchyma of the pancreas. Upstream dilatation of
main pancreatic duct was also noted. Neither evidences
of distant metastasis nor direct invasion to adjacent
organs were detected. In addition, CT scan showed that
enlarged lymph nodes were not detected throughout
the body including in peri-pancreatic region.
Magnetic resonance imaging (MRI) showed that the
solid round mass had heterogeneous signal intensity on
a T1- and T2-weighted image. In addition, gadolinium-
enhanced MRI revealed that the mass was heteroge-
neously enhanced in the pancreatic body (Fig. 1c).
Endoscopic retrograde pancreatography (ERP) showed
that main pancreatic duct was slightly deviated down-
ward because of locoregional pressure effect, but direct
invasion to the main pancreatic duct was not evident
(Fig. 1d).
Neuroendocrine neoplasms, acinar cell carcinoma, and
ductal adenocarcinoma variants such as clear cell carcin-
oma, or solid-pseudopapillary neoplasm, were suggested
before operation. Since malignant tumor could not be
denied according to the preoperative imaging studies,
she underwent pancreaticoduodenectomy to establish a
definitive diagnosis.
Table 1 Laboratory data
•Hematology •Tumor marker
WBC 4600/mm3 CEA 0.7 ng/ml
RBC 349 × 104/mm3 CA19-9 7.7 U/ml
Hb 9.9 g/dl AFP 1.6 ng/ml
Ht 23.20 % Elastase 1 173 ng/dl
Plt 23.2 × 104 /mm3 SPAN-1 11 U/ml
DUPAN-2 <25 U/ml
•Blood chemistry
TP 7.9 g/dl •Endocrinology
Alb 4.3 g/dl Gastrin (<200) 370 pg/ml
T.Bil 0.7 mg/dl Glucagon (40~180) 81 pg/ml
AST 27 IU/L IRI (0~16) 7.8 μU/ml
ALT 15 IU/L VIP (<100) 11 pg ml
LDH 265 IU/L Serotonin (40~350) 47 ng/ml
ALP 220 IU/L Somatostatin (1.0~12) 23 pg/ml
ɤ-GTP 12 IU/L
Glucose 94 mg/dl •Serology





Fig. 1 Imaging studies. a Ultrasonography showed that gourd-shaped hypo- and iso-echoic mass, 56 mm in size, was detected in the pancreatic
head and body. b Enhanced computer tomography showed that solid well-circumscribed low-density mass, 7 cm in diameter, was located in the
pancreatic head and body. c Heterogeneously enhanced mass was detected in the pancreatic body by gadolinium-enhanced MRI. d Endoscopic
retrograde pancreatography (ERP) showed that main pancreatic duct was slightly deviated downward because of locoregional pressure effect,
but direct invasion to the main pancreatic duct was not evident
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Macroscopically resected specimen showed a well-
circumscribed vaguely lobulated mass, 6 cm in diameter,
distributed mainly in the ventral side of the pancreatic
head and body (Fig. 2a). The cut surface of the resected
specimen revealed the brownish-colored encapsulated
solid mass associated with hemorrhage at the body of
the pancreas (Fig. 2b). Neither pancreatic duct change
(stenosis, dilatation) nor common bile duct dilatation
was evident in these specimens.
Microscopically, the tumors were composed of epithe-
lioid tumor cells possessing clear to focally granular
eosinophilic cytoplasm, centrally located, round to oval
nucleus and inconspicuous nucleoli, diffusely prolifer-
ated in solid nests or alveolar pattern with sinusoidal
vasculatures. Neither necrosis, calcification, lipomatous
component, infiltrative growth pattern, mitotic figures
nor vessels permeation was evident. The tumor was
sharply demarcated from the pancreatic parenchyma by
thick fibrous tissue (Fig. 2c, d). Results of immunohisto-
chemical and special stain were summarized in Table 2.
The tumor cells had cytoplasmic periodic acid-Schiff
positive granules, which were completely digested by
diastase, indicating these granules as glycogen. Immuno-
histochemically, these tumor cells are positive for
neuron-specific enolase (NSE) and human melanoma
black 45 (HMB-45), but negative for myogenic markers
(α-smooth muscle actin (α-SMA) and HHF-35), epithe-
lial markers (AE1/AE3, CAM5.2), endocrine markers
(synaptophysin, chromogranin A), and acinar markers
(trypsin and α-1-antitrypsin) (Fig. 3). These morphological
and immunohistochemical features indicate PEComa.
Ki-67 labeling index was less than 1 %.
The postoperative course was uneventful, and she
discharged 18 days after surgical operation without
impaired glucose tolerance. The patient is doing well
and free of recurrence 12 years after surgical resection.
Discussion
PEComa is a term that WHO defined as “a mesenchymal
tumor composed of histologically and immunohisto-
chemically distinctive perivascular epithelioid cells (PECs)”
Fig. 2 Macro- and microscopic findings of the resected specimens. a Well-circumscribed vaguely lobulated mass distributed mainly in the ventral
side of the pancreatic head and body. b The cut surface of the resected specimen revealed that the brownish-colored encapsulated mass was
solid associated with hemorrhage and contiguous to the pancreas. c, d Histological findings showed that the tumors were composed of perivascularly
arranged epithelioid tumor cells possessing clear to focally granular eosinophilic cytoplasm, round to oval nucleus and inconspicuous nucleoli, diffusely
proliferated in solid nests or alveolar pattern with sinusoidal vasculatures (hematoxylin and eosin stain C ×100, D ×400)
Table 2 Results of immunohistochemical stain
Positive Negative
PAS PAS with diastase digestion
Fontana-Masson Cytokeratins (CAM5.2, AE1/AE3)
HMB-45 Epithelial membrane antigen (EMA)
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[1]. The PECs are characterized by epithelioid or spindle-
shaped appearance with a clear, eosinophilic, or granular
cytoplasm, a round to oval, centrally located nucleus and
an inconspicuous nucleolus. Immunohistochemical stain
shows that the tumor cells are positive for HMB-45 and
occasionally positive for α-SMA, S-100, and desmin, but
negative for cytokeratins and endocrine markers [2].
Diffuse immunoreactivities for HMB-45 confirm that the
tumor cells have melanocytic features.
By morphological and immunohistochemical simi-
larity, PEComa family encompasses angiomyolipoma,
lymphangioleiomyoma, and clear cell “sugar” tumor [3].
PEComa arise in various organs throughout the body,
especially in soft tissue, bone, abdominopelvic sites, or
retroperitoneal site such as the kidney, uterus, and
gastrointestinal tract, but PEComa arising in pancreas is
extremely rare [4]. Since Zamboni et al. firstly reported
pancreatic clear cell “sugar” tumor in 1996 [5], 14 re-
ports of this tumor family arising in pancreas were docu-
mented including this report [5–17]. Previously reported
pancreatic PEComas were summarized in Table 3. The
patient group consisted of 12 women and 2 men, indi-
cating female predominance. In addition, these tumors
can arise in any age of patients (age range from 17 to 74;
mean age of 49.4 years) but typically found in middle-
aged to elderly women. Tumors were located in pan-
creatic head in six patients, in pancreatic body in six
patients, and in uncinated process in two patients, indi-
cating that this tumor family could arise anywhere in the
pancreas. The mean tumor size was 3.9 cm (range from
1.5 to 10 cm). Primary symptoms included abdominal
pain in nine patients, diarrhea, melena, fever, and bulge
in stomach in one patient, respectively. Ultrasonography
for follow-up of hepatic hemangioma revealed pancreatic
head mass in one patient without chief complaint [13].
Histological diagnosis of these tumors was PEComa in
ten patients, malignant PEComa in one patient, angio-
myolipoma in one patient, and clear cell sugar tumor in
two patients. These tumors contained varying propor-
tions of epithelioid cell and spindle-shaped cell compo-
nents [2] and associated with glycogen granules in nine
patients, necrosis in two patients, and hemorrhage in six
patients. In our patient, the tumor was composed mostly
of epithelioid cells with clear cytoplasm, and spindle-
shaped tumor cells are inconspicuous in these speci-
mens. Glycogen granules and hemosiderin deposition
are also noted, but tumor necrosis is not observed.
Immunohistochemically, all the patients suffering pan-
creatic PEComa exhibited immunoreactivity for HMB-
45 and αSMA except for two patients including our
patient. S-100 immunoreactivity was observed in one
patient and focally observed in four patients, and the
others were negative. Desmin immunoreactivity was
observed in one patient, and the others were negative as
we could retrieve. Neither endocrine nor epithelial
markers exhibited immunoreactivities. Myogenic marker,
αSMA, exhibited immunoreactivity in spindle-shaped
cells with muscular feature, and smooth muscle actin
was found in 80 % of PEComa patients [2, 18]. In the
present case, the tumor cells were negative for αSMA,
different from other previously reported pancreatic





Fig. 3 Immunohistochemical analyses. a, b The tumor cells (arrow) revealed cytoplasmic immunoreactivities for melanocytic marker, HMB-45, but
negative for epithelial marker, CAM5.2. In normal pancreatic tissue (asterisk), CAM5.2 was diffusely positive, but very confined immunoreactivity was
shown for HMB-45. c, d The tumor cells are negative for S-100 and α-smooth muscle actin (α-SMA). Sinusoidal vasculatures were positive for α-SMA
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was composed mostly of epithelioid cells in our patient
[4]. Ki-67 labeling index was less than 1 % in large pro-
portion of pancreatic PEComa patients including our pa-
tient except for one patient with less than 5 %. Prognosis
of pancreatic PEComa is good, most patients remained
free of relapse; however, followed-up period was only
within 1 year except for the patient for 5 years. Our
patient has been no sign of recurrence for 12 years.
Thus, our case is the first report of long-term follow-up
of PEComa of the pancreas over 10 years.
Table 3 Summary of previous reports of pancreatic PEComa








Zamboni 1996 60 F - abdominal
pain
body DP 2 clear cell sugar
tumor
epithelioid




PPPD 4.7 angiomyolipoma epithelioid
Ramuz 2005 31 F - abdominal
pain
body SPDP 1.5 sugar tumor epithelioid
Perigny 2008 46 F N.A diarrhea body Enucleation 1.7 PEComa spindle > epithelioid
Hirabayashi 2009 47 F - abdominal
pain
head PPPD 1.7 PEComa spindle
Baez 2009 60 F - abdominal
bulge
body DP 3.5 PEComa
(sugar tumor)
epithelioid + spindle
Zemet 2011 49 M - fever, cough
and malaise
head PPPD 4 PEComa epithelioid smooth
muscle cells
Nagata 2011 52 M - abdominal
pain
head PD 4 PEComa epithelioid
Finzi 2012 62 F - none head Total
excision
2.5 PEComa epithelioid




PD 1.8 PEComa epithelioid + spindle




DP 10 PEComa spindle
Mourra 2013 51 F - abdominal
pain, jaund:
head PD 6 malignant
PEComa
epithelioid
Petrides 2015 17 F N.A melena,
anemia
head PPPD 4.2 PEComa epithelioid + spindle
Our
patient
2015 61 F - abdominal
pain
body PD 7 PEComa epithelioid
Glycogen
granules
Necrosis Mitosis Ki-67 LI Hemorrhage α-SMA HMB45 S-100 Desmin Endocrine
markers
Cytokeratins Recurrence Follow up
+ N.A - <1% focally + + + focally + N.A - - - 3 months
N.A - N.A N.A + + + - N.A - - - 69 months
+ - - <1% - focaly + + focally + - - - - 9 months
+ - 1/50HPF N.A N.A + + focally + N.A N.A CK1 + - 3 months
+ - 1/10HPF <1% - + + + - - - - 12 months
+ - Rare N.A N.A + + N.A + N.A - - 7 months
+ - - <1% N.A + + N.A N.A N.A - - 10 months
N.A N.A 1/50HPF N.A + N.A + N.A N.A N.A - Liver 27 months
+ N.A Rare 8% N.A + + focally + N.A - - - 5 months
+ N.A N.A N.A N.A + + - N.A - - N.A N.A
N.A + N.A <5% + + + - N.A N.A - - 7 months
+ + 2/50HPF N.A + - + - - N.A - Liver 6 months
N.A N.A infrequent N.A N.A + + - - - - - 18 months
+ - - <1% + - + - - - - - 12 years
DP distal pancreatectomy, PPPD pylorus preserving pancreaticoduodenectomy, PD pancreaticoduodenectomy
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Differential diagnoses of pancreatic PEComa were
included epithelial tumors such as primary clear cell
carcinoma, metastatic renal cell carcinoma, endocrine
tumor with clear cell change, solid pseudopapillary
neoplasm, and acinar cell carcinoma. It is relatively easy to
distinguish this entity from the other possible diseases in
surgical resected specimen by immunohistochemical
study for epithelial markers, neuroendocrine markers,
acinar markers, myogenic markers, and HMB-45. Re-
cently, clear cell sarcoma arising in pancreas was reported
by Huang et al. [19]. This rare malignant soft tissue
neoplasm affects young adult, has a poor prognosis, and
expresses melanocytic marker, HMB-45. We could rule
out this tumor entity because S-100 protein immunoreac-
tivity was low in the tumor of our patient.
Tuberous sclerosis is a systemic genetic disease that
caused seizures, intellectual disability, and benign tumor
development in multiple organs including the brain and
skin [2, 20, 21]. Recent study mentioned that mTOR
inhibitor was effective in PEComa associated with tuber-
ous sclerosis because of mTOR pathway upregulation
[22]. Although many lesions of PEComa family observed
in tuberous sclerosis complex patients, there are no pan-
creatic PEComa patients having a history of tuberous
sclerosis complexes to the extent that we could retrieve,
possibly suggesting that pancreatic PEComa has little as-
sociation with tuberous sclerosis complexes.
Folpe et al. reported in 2005 that the presence of tumor
recurrence or metastasis was predicted by worrisome fea-
tures in PEComa arising from soft tissue and gynecologic
origins [2]. Worrisome features included large size (>5 cm),
infiltrative growth, high nuclear grade, hypercellularity, ne-
crosis, and high mitotic figures (>1/50 HPF). Previous re-
ports in pancreatic PEComa revealed liver metastasis in
two patients. When we adapted these worrisome features
to pancreatic PEComa and retrieved these features as we
can from the literatures about these two recurrent tumors,
we found necrosis in one patient, and mitotic figures are
sparsely seen (2/50HPF and 1/50HPF, respectively), but the
other features are lacking in these tumors. In our patient,
the tumor is 6 cm in size and mitoses are seen (1/50HPF),
thus applicable to two worrisome features of PEComa aris-
ing from the soft tissue and gynecologic organs, but our pa-
tient is free of recurrence 12 years after surgery.
As pancreatic PEComa is difficult to diagnose preopera-
tively, extensive resection with lymph nodes dissection
such as pancreaticoduodenectomy and distal pancreatec-
tomy was performed in 12 patients including our patients,
whereas two patients underwent local excision. Lymph
node relapse was not seen in the patients of pancreatic
PEComa, suggesting that lymph node dissection might be
omitted in pancreatic PEComa.
In our patient, serum levels of gastrin and somato-
statin were slightly elevated in contrast to the other
reports of PEComa, but the cause of elevating these
hormones is not determined in other blood tests and
imaging studies. Furthermore, immunohistochemical
staining revealed the tumor cells were negative for
gastrin or somatostatin.
Since clinical experience of pancreatic PEComa is very
limited, the accumulation of this disease’s reports is
required to define the worrisome features as an indicator
of recurrence and metastasis of pancreatic PEComa, and
since the tumor can recur, we recommend complete
resection and careful follow-up.
Conclusions
We reported the patient with PEComa arising in pancre-
atic body with characteristic immunohistological features.
We suggest that clinicians should be aware of pancreatic
PEComa in diagnosing a patient with pancreatic mass, if
there are findings suspicious for neoplasm with clear cell
features including clear cell carcinoma, acinar cell carcin-
oma, or solid pseudopapillary neoplasm in preoperative
imaging studies or EUS-guided biopsy samples.
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